• Company
  • Description
  • Recovery Amount
  • Merck (securities)
  • In re Merck & Co., Inc. Vytorin/Zetia Securities Litigation
  • $215 million

 

District of New Jersey

G&E served as co-lead counsel representing a foreign public pension fund and other funds in a securities class action suit against Merck & Co. after the drugmaker’s stock price plummeted and shareholders lost billions of dollars. The claims stemmed from a 2006 clinical trial called the ENHANCE study, which indicated that Merck’s anti-cholesterol drug Vytorin (a combination of Schering-Plough’s drug Zetia and Merck’s much cheaper and widely available Simvastatin, formerly known as Zocor), had no statistical advantage in treating atherosclerosis when compared to use of Simvastatin alone. The company settled the case just prior to trial, which was scheduled to begin on March 4, 2013.